Cargando…
P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428987/ http://dx.doi.org/10.1097/01.HS9.0000969172.27202.d1 |
| _version_ | 1785090602948362240 |
|---|---|
| author | Fleming, Shaun Roboz, Gail T. Fathi, Amir Y. Zhang, Tian Wei, Andrew Carraway, Hetty Holes, Leanne Petrlik, Erica Prebet, Thomas Lopes De Menezes, Daniel Bluemmert, Iryna Sun, Hao Ravandi, Farhad |
| author_facet | Fleming, Shaun Roboz, Gail T. Fathi, Amir Y. Zhang, Tian Wei, Andrew Carraway, Hetty Holes, Leanne Petrlik, Erica Prebet, Thomas Lopes De Menezes, Daniel Bluemmert, Iryna Sun, Hao Ravandi, Farhad |
| author_sort | Fleming, Shaun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428987 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104289872023-08-17 P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA Fleming, Shaun Roboz, Gail T. Fathi, Amir Y. Zhang, Tian Wei, Andrew Carraway, Hetty Holes, Leanne Petrlik, Erica Prebet, Thomas Lopes De Menezes, Daniel Bluemmert, Iryna Sun, Hao Ravandi, Farhad Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428987/ http://dx.doi.org/10.1097/01.HS9.0000969172.27202.d1 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Fleming, Shaun Roboz, Gail T. Fathi, Amir Y. Zhang, Tian Wei, Andrew Carraway, Hetty Holes, Leanne Petrlik, Erica Prebet, Thomas Lopes De Menezes, Daniel Bluemmert, Iryna Sun, Hao Ravandi, Farhad P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA |
| title | P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA |
| title_full | P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA |
| title_fullStr | P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA |
| title_full_unstemmed | P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA |
| title_short | P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA |
| title_sort | p567: phase 1b omniverse trial: safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428987/ http://dx.doi.org/10.1097/01.HS9.0000969172.27202.d1 |
| work_keys_str_mv | AT flemingshaun p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT robozgail p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT tfathiamir p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT yzhangtian p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT weiandrew p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT carrawayhetty p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT holesleanne p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT petrlikerica p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT prebetthomas p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT lopesdemenezesdaniel p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT bluemmertiryna p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT sunhao p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia AT ravandifarhad p567phase1bomniversetrialsafetyandtolerabilityoforalazacitidineincombinationwithvenetoclaxfortreatmentofacutemyeloidleukemia |